---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-22-000007"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2022-04-26T23:59:59+00:00"
generated_at: "2026-06-26T04:30:36.314089+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edwards Q1 sales $1.34B (+13% underlying), adjusted EPS $0.60; TAVR up 14% underlying

## Summary
- Q1 sales $1.34B, up 10% reported (13% underlying); adjusted EPS $0.60.
- TAVR sales $881M (+11% reported, +14% underlying); global TAVR opportunity seen doubling to $10B by 2028.
- Full-year 2022 guidance: sales $5.5-6.0B, adjusted EPS $2.50-$2.65; Q2 sales $1.36-1.44B.
- MITRIS RESILIA valve for mitral position received US FDA approval and launched commercially.
- Repurchased ~$400M stock in Q1; free cash flow $221M; cash $1.5B.

## SEC filing metadata
- accession: 0001099800-22-000007
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2022-04-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000007/0001099800-22-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980022000007/ew-20220426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-22-000007
- JSON: https://secwatch.observer/filing/0001099800-22-000007.json
- Plain text: https://secwatch.observer/filing/0001099800-22-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.